Market openNon-fractional

Stoke Therapeutics/STOK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Stoke Therapeutics

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Ticker

STOK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Bedford, United States

Employees

110

STOK Metrics

BasicAdvanced
$660M
Market cap
-
P/E ratio
-$2.42
EPS
0.81
Beta
-
Dividend rate
$660M
0.81
5.431
5.018
2.939
4.516
-30.41%
-61.29%
72.561
4.21
4.21
-6.638
-46.12%
-1.94%
12.77%

What the Analysts think about STOK

Analyst Ratings

Majority rating from 9 analysts.
Buy

STOK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-626.19% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$4.2M
50.00%
Net income
-$26M
-2.23%
Profit margin
-626.19%
-34.82%

STOK Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.56%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.69
-$0.55
-$0.60
-$0.57
-
Expected
-$0.64
-$0.63
-$0.63
-$0.61
-$0.55
Surprise
8.43%
-12.41%
-4.76%
-6.56%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Stoke Therapeutics stock?

Stoke Therapeutics (STOK) has a market cap of $660M as of July 05, 2024.

What is the P/E ratio for Stoke Therapeutics stock?

The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 0 as of July 05, 2024.

Does Stoke Therapeutics stock pay dividends?

No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Stoke Therapeutics dividend payment date?

Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.

What is the beta indicator for Stoke Therapeutics?

Stoke Therapeutics (STOK) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Stoke Therapeutics stock

Buy or sell Stoke Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing